HemoClear B.V.

Transforming Blood Transfusions: A Pioneering Vision

At HemoClear, we are revolutionizing the accessibility and affordability of blood transfusions worldwide through our groundbreaking technology in autologous blood transfusions. Since our inception, our mission has been clear: to facilitate safer, more economical blood management solutions that can be easily adopted globally, particularly in under-served regions.

Innovative Solutions and Market Entry

In 2022, HemoClear introduced a pioneering product to the market—the first micro-filtration cell salvage filter. This validated, single-use device exceeds the current standards of patient blood management. It is fully protected under intellectual property laws and has secured full EU CE registration, positioning us in a market with a potential worth of $45 billion.

Our micro-filtration technology is a game-changer. It offers a swift, 30-minute bedside procedure that utilizes gravity to transform patient perioperative collected shed blood into safe and high quality transfusion blood. This not only maximizes transfusion blood availability, safety and efficacy but also ensures a reduction in the common risks associated with donor blood transfusions such as infections and prolonged recovery times.

Global Impact and Expansion

In 2024, HemoClear has strategically expanded operations, not just across the European Union but globally, with a significant focus on penetrating low-income countries. Our collaboration with NGOs and governmental bodies, including a crucial partnership with the Nigerian government, aims to mitigate their annual deficit of 1.7 million units of blood. This venture underscores our commitment to addressing global health challenges through innovative, scalable solutions.

Certifications and Approvals

Our commitment to quality and reliability is evidenced by our adherence to the highest standards. HemoClear is proud to hold ISO 13485 and CE certifications. Our facilities in the Netherlands are at the forefront of our innovation, supported by a successful FDA 510K pre-assessment that promises future growth and opportunities in additional markets.

Market Opportunity and Growth Potential

Within the global $45 billion 'blood'market, theautotransfusion devices, currently valued at approximately €4 billion, is projected to grow at a CAGR of 6.1%. Our product directly addresses the critical shortcomings of existing autotransfusion devices by offering a safer, more efficient, and cost-effective solution.

Financial Outlook and Investment Invitation

With anticipated revenues reaching €500K in 2024, HemoClear is at a pivotal point of growth. We are seeking an investment of €10 million to significantly scale up our production capabilities and expand our medical, marketing, and sales operations. This capital infusion will also bolster our entry into new markets and reinforce our position in existing ones, aiming to meet and exceed our strategic growth objectives.

Conclusion

HemoClear B.V. stands at the forefront of a healthcare revolution, with a robust operational foundation and dynamic growth plans aimed at improving global health outcomes. We invite you to be part of this transformative journey. Let's discuss how.